Upload
shon-lee
View
216
Download
1
Embed Size (px)
Citation preview
+
Class is Cancelled! Tuesday, Oct 16thMidterm #1 – Thursday, Oct. 4th
+Assignment Due March 5th
Sign-up sheet for “lab component” located outside my office (Sn 1061)
Sign-up for 1 hour slot – 4 people/time slot Monday, Feb 11 - Friday, Feb 15
+
Anatomy Basics
Major Division Ventricle Subdivision Principle Structures
Midbrain
Hindbrain
Forebrain
Lateral
Third
Telencephalon
Diencephalon
Cerebral cortex
Basal ganglia
Limbic System
Cerebralaqueduct Mesencephalon
Metencephalon
TectumTegmentum
Fourth
Cerebellum
Pons
Myelencephalon
Thalamus
Hypothalamus
Medulla oblongata
+
Psychopharmacology
Chapter 4
Mind and Brain
+Chapter Preview
Principles of Psychopharmacology
Sites of Drug Action
Neurotransmitters and Neuromodulators
+Introduction
Psychopharmacology The study of the effects of drugs on the nervous
system and behavior Drug effects – the changes a drug produces in an
animal’s physiological processes and behavior Sites of action – the locations at which molecules of
drug interact with molecules located on or in cells of the body, thus affecting some biochemical processes of these cells.
+Principles of Psychopharmacology
Pharmacokinetics The process by which drugs are absorbed, distributed
within the body, metabolized, and excreted.
+Principles of Psychopharmacology Routes of Administration
Intravenous (IV) Injection – injection of a substance directly into a vein. Drug enters bloodstream immediately and
reaches the brain in seconds
+Principles of Psychopharmacology Routes of Administration
Intraperitoneal (IP) Injection – injection of a substance into the peritoneal cavity, the space that surrounds the stomach, intestines, liver, and other abdominal organs. Most common route for small laboratory animals
+Principles of Psychopharmacology Routes of Administration
Intramuscular (IM) Injection – injection of a substance into a muscle.
+Principles of Psychopharmacology Routes of Administration
Subcutaneous (SC) Injection – injection of a substance into the space beneath the skin.
+Principles of Psychopharmacology Routes of Administration
Oral Administration – administration of a substance into the mouth so that it is swallowed.
Sublingual Administration – administration of a substance by placing it beneath the tongue.
+Principles of Psychopharmacology Routes of Administration
Intrarectal Administration – administration of a substance into the rectum.
Inhalation – administration of a vaporous substance into the lungs.
Topical Administration – administration of a substance directly onto the skin or mucous membrane. Insufflation – sniffing drugs; contacts mucous
membranes of the nasal passages; sniffing not same as inhalation!
+Principles of Psychopharmacology Routes of Administration
Intracerebral Administration – administration of a substance directly into the brain.
Intracerebroventricular (ICV) Administration – administration of a substance into one of the cerebral ventricles.
+Principles of Psychopharmacology
Distribution of Drugs Within the Body Lipid Solubility – ease with drug molecules are
soluble in fat. Heroin more lipid soluble than morphine so gets
to brain faster; more intense ”rush” Depot Binding – binding of a drug with various
tissues of the body or with proteins in the blood. If drug bound to depot cannot reach site of action
Albumin – a protein found in the blood; serves to transport free fatty acids and can bind with some lipid-soluble drugs.
+
Depot Binding with Blood Albumin ProteinFigure 4.2
+Principles of Psychopharmacology
Inactivation and Excretion Enzymes deactivate drugs (e.g., liver). Drugs are eventually excreted (e.g., kidneys).
+Principles of Psychopharmacology
Drug Effectiveness Dose-Response Curve – a graph of the magnitude
of an effect of a drug as a function of the amount of drug administered.
+Figure 4.3 A Dose-Response Curve
Usually defined as mg of drug/Kg of body weight
+Principles of Psychopharmacology
Drug Effectiveness Sites of actions Affinity – the readiness with which two molecules join
together Many drugs have more than one effect, which should
be taken into consideration when determining the effect dose for treatment.
+Figure 4.4 Dose-Response Curves for Morphine
+Principles of Psychopharmacology
Therapeutic Index – the ratio between the dose that produces the desired effect in 50% of the animals and the dose that produces toxic effects in 50% of the animals. If toxic dose is 5 times higher than the effective
dose then the TI = 5 The lower the TI, the more care must be taken in
prescribing the drug
+Principles of Psychopharmacology
Effects of Repeated Administration Tolerance – a decrease in the effectiveness of a drug
that is administered repeatedly. Withdrawal Symptom – the appearance of
symptoms opposite to those produced by a drug when the drug is administered repeatedly and then suddenly no longer taken.
Sensitization – an increase in the effectiveness of a drug that is administered repeatedly.
+Principles of Psychopharmacology
Placebo Effects An inert substance that is given to an organism in lieu
of a physiologically active drug; used experimentally to control for the effects of mere administration of a drug.
+Sites of Drug Action
Most drugs that affect behavior affect synaptic transmission
Two categories: Antagonists – Drugs that oppose or inhibit the
effects of a particular neurotransmitter on the postsynaptic cell.
Agonists – Drugs that facilitate the effects of a particular neurotransmitter on the postsynaptic cell.
+Review of steps in synaptic transmission (Chapter 2)
Neurotransmitters are synthesized and stored in synaptic vesicles
Vesicles travel to presynaptic membrane and dock
Axon fires and voltage-dependent calcium channels open allowing calcium ions to enter
Calcium ions interact with docking proteins causing release of neurotransmitter into synaptic cleft
Neurotransmitter binds to postsynaptic receptor, ion channels open, PSPs produced
Effects of neurotransmitter kept brief by reuptake or enzymatic degradation
Stimulation of autoreceptors regulates synthesis and release of neurotransmitter
+Sites of Drug Action
Act on Neurotransmitters Enzymes control the synthesis of a neurotransmitter
from its precursors. Rate of synthesis and release can be increased by
administering the precursor The precursor serves as an agonist (step 1 in
Figure 4.5) If a drug inactivates the enzymes it prevents the
neurotransmitter from being produced It serves as an antagonist (step 2 in Figure 4.5)
+Figure 4.5 Drug Affects on Synaptic Transmission
+Sites of Drug Action
Effects on Storage and Release of Neurotransmitters Drugs may exert their agonistic or antagonistic effects by
influencing the storage and release of neurotransmitters. Some drugs can prevent the storage of neurotransmitter
in the vesicles – antagonists (step 3 in Figure 4.5) Some drugs can also prevent the release of
neurotransmitters by deactivating proteins that cause synaptic vesicles to fuse with presynaptic membrane (step 5 in Figure 4.5)
Other drugs act as agonists by triggering the release of neurotransmitter (step 4)
+Figure 4.5 Drug Affects on Synaptic Transmission
+Sites of Drug Action
Effects on Receptors Drugs may exert their agonistic or antagonistic
effects by influencing receptors. Direct Agonist – a drug that binds with and
activates a receptor; mimics the effects of a neurotransmitter (step 6 in Figure 4.5).
Direct Antagonist – a drug that binds with a receptor but does not activate it; prevents the natural ligand from binding with the receptor; also called receptor blocker (step 7 in Figure 4.5).
+Figure 4.5 Drug Affects on Synaptic Transmission
+Sites of Drug Action
Noncompetitive Binding – binding of a drug to a site on a receptor; does not interfere with the binding site for the principal ligand.
Indirect Antagonist – a drug that attaches to a binding site on a receptor and interferes with the action of the receptor; does not interfere with the binding site for the principal ligand.
Indirect Agonist – a drug that attaches to a binding site on a receptor and facilitates the action of the receptor; does not interfere with the binding site for the principal ligand.
+Figure 4.6 Drug Actions at Binding Sites
+Sites of Drug Action
Autoreceptors – regulate the amount of neurotransmitter released Drugs that activate these receptors serve as
antagonists, decreasing the amount of neurotransmitter released (step 8 in Figure 4.5)
Drugs that block the presynaptic autoreceptors increase the release of neurotransmitter (step 9 in Figure 4.5)
+Figure 4.5 Drug Affects on Synaptic Transmission
+Sites of Drug Action
Some terminal buttons form axoaxonic synpases
Presynaptic Heteroreceptor – a receptor located in the membrane of a terminal button that receives input from another terminal button by means of an axoaxonic synapse; binds with the neurotransmitter released by the presynaptic terminal button.
+Figure 4.7 Presynaptic Heteroreceptors
+Figure 4.8 Dendritic Autoreceptors
+Sites of Drug Action
Effects on Reuptake or Destruction of Neurotransmitters Drugs can attach to transporter molecules
responsible for reuptake and inactivate them Drugs can bind with the enzyme that normally
destroys the neurotransmitter and prevent it from working
Both types of drugs prolong the presence the neurotransmitter in the synaptic cleft – agonists (steps 10 and 11 in Figure 4.5).
+Figure 4.5 Drug Affects on Synaptic Transmission